EMA Boosts Transparency On Maintaining Orphan Status At Time Of Approval
Executive Summary
New orphan maintenance assessment reports are expected to increase transparency around the European Medicines Agency's decision-making process on whether an orphan-designated drug continues to qualify as an orphan once it gets on to the market.